EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers

Steven K Sutton, Kea Turner, Katherine Chung-Bridges, Susan T Vadaparampil, Rania Abdulla, Mariana Arevalo, Natasha Avrilien, Margaret M Byrne, Edelise Endemano, Jennifer Garcia Hernandez, Jada G Hamilton, Erin Lyjak und 6 weitere

Contemporary Clinical Trials · 2026

DOI: 10.1016/j.cct.2026.108439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Contemporary Clinical Trials, 2026. Verfasst von Steven K Sutton und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Steve.Sutton@moffitt.org. Hauptthemen laut MEDLINE: Patient Education as Topic, Skin Neoplasms. Die Arbeit nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Skin cancers are the most common type of cancer in the United States, occur in all segments of the population, and are preventable. Our previous research with primary care patients' demonstrated interest in and efficacy of a precision prevention intervention providing feedback on MC1R risk level (higher versus average) in combination with prevention education materials relative to a standard educational intervention. Our current study is a hybrid type 1 effectiveness-implementation trial deployed at six federally-qualified health centers. This paper presents the study protocol. METHODS: A community advisory panel will guide development of study materials and measures. Staff training at each clinic will be completed in-person. Patients will be approached and screened in-person. Those completing genetic testing and the baseline survey will be randomized to the precision versus standard intervention for each risk level with a target sample size of 286 for each combination. Primary outcomes of effectiveness, assessed at 6 and 12 months, include a tanning score (5 items assessing intentional and unintentional tanning), number of sunburns, conduct of a skin self-examination, and electronic health record documentation of clinician-patient communication about skin cancer prevention. Effectiveness comparisons will focus on the precision relative to the standard intervention among higher risk participants. Implementation data will be collected to identify barriers and facilitators. RESULTS: Effectiveness and implementation outcomes will be evaluated following study completion. CONCLUSIONS: Results will guide subsequent scale-up of the precision intervention, including modifications of the intervention as well as methods for implementation. CLINICAL TRIALS IDENTIFIER: NCT07222995.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Education as TopicSkin NeoplasmsFemaleHumansFeedbackGenetic TestingPrimary Health CareResearch DesignRisk AssessmentSelf-ExaminationSunburnUnited StatesRandomized Controlled Trials as TopicMulticenter Studies as TopicMale

Stichwörter der Autor:innen

Genetic riskHybrid type 1InterventionPreventionSkin cancer

Autor:innen und Institutionen

  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Steve.Sutton@moffitt.org.
  • Division of Health Systems, Policy, and Innovation, School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: Kea.turner@unc.edu.
  • Health Choice Network, Miami, FL, USA. Electronic address: kchung@hcnetwork.org.
  • Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: susan.vadaparampil@moffitt.org.
  • Non-Therapeutic Research Office, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Rania.Abdulla@moffitt.org.
  • Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: mariana.arevalo@moffitt.org.

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Sutton, S. K., Turner, K., Chung-Bridges, K., Vadaparampil, S. T., Abdulla, R., Arevalo, M., Avrilien, N., Byrne, M. M., Endemano, E., Garcia Hernandez, J., Hamilton, J. G., Lyjak, E., Parrales, Z., Ramos, J., Torres, M., White, B., Hay, J. L., & Kanetsky, P. A. (2026). A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2026.108439

Vancouver

Sutton SK, Turner K, Chung-Bridges K, Vadaparampil ST, Abdulla R, Arevalo M, et al. A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers. Contemporary Clinical Trials. 2026. doi:10.1016/j.cct.2026.108439

BibTeX
@article{Sutton2026,
  author = {Sutton, Steven K and Turner, Kea and Chung-Bridges, Katherine and Vadaparampil, Susan T and Abdulla, Rania and Arevalo, Mariana and Avrilien, Natasha and Byrne, Margaret M and Endemano, Edelise and Garcia Hernandez, Jennifer and Hamilton, Jada G and Lyjak, Erin and Parrales, Zoe and Ramos, Jairo and Torres, Maritza and White, Brian and Hay, Jennifer L and Kanetsky, Peter A},
  title = {A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers},
  journal = {Contemporary Clinical Trials},
  year = {2026},
  doi = {10.1016/j.cct.2026.108439}
}
Kostenlos starten →